share_log

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics | 8-K：SERA 預測報告了 2024 年第二季度財務業績
美股SEC公告 ·  2024/08/08 04:19

Moomoo AI 已提取核心訊息

Sera Prognostics reported Q2 2024 revenue of $24,000, down from $123,000 in Q2 2023. The company achieved a 20% reduction in total operating expenses to $9.3 million, leading to a narrower net loss of $8.3 million compared to $10.5 million year-over-year. Research and development expenses increased 19% to $4.4 million, while selling, general and administrative costs decreased 38% to $4.9 million.The company highlighted recent achievements including the publication of positive AVERT PRETERM TRIAL results and conditional approval from New York State for ambient whole-blood collection. The final PRIME study database lock is anticipated by mid-September, with publication targeted for spring pregnancy conferences.Management is executing various cost-effective programs to educate physicians and patients about their PreTRM® Test, including partnerships with medical professional platforms and multi-channel marketing strategies. The company maintains focus on building evidence portfolio and establishing care guidelines to drive adoption and revenue growth.
Sera Prognostics reported Q2 2024 revenue of $24,000, down from $123,000 in Q2 2023. The company achieved a 20% reduction in total operating expenses to $9.3 million, leading to a narrower net loss of $8.3 million compared to $10.5 million year-over-year. Research and development expenses increased 19% to $4.4 million, while selling, general and administrative costs decreased 38% to $4.9 million.The company highlighted recent achievements including the publication of positive AVERT PRETERM TRIAL results and conditional approval from New York State for ambient whole-blood collection. The final PRIME study database lock is anticipated by mid-September, with publication targeted for spring pregnancy conferences.Management is executing various cost-effective programs to educate physicians and patients about their PreTRM® Test, including partnerships with medical professional platforms and multi-channel marketing strategies. The company maintains focus on building evidence portfolio and establishing care guidelines to drive adoption and revenue growth.
Sera Prognostics報告2024年第二季度營業收入爲24,000美元，較2023年第二季度的123,000美元下降。公司實現了營業費用減少20%，降至930萬，導致淨虧損收窄至830萬，同比相比於1050萬。研究與開發費用增加19%，達到440萬，而銷售、一般及行政費用減少38%，降至490萬。公司強調最近的成就，包括正面結果的AVERt PRETERm試驗報告以及來自紐約州的環境全血採集的有條件批准。最終的PRIME研究數據庫預計將在九月中旬鎖定，出版目標爲春季懷孕會議。管理層正在執行各種成本有效的項目，以教育醫生和患者關於他們的PreTRM®測試，包括與醫療專業平台的合作和多渠道營銷策略。公司繼續專注於建立證據組合和制定護理指南，以推動採用和營業收入增長。
Sera Prognostics報告2024年第二季度營業收入爲24,000美元，較2023年第二季度的123,000美元下降。公司實現了營業費用減少20%，降至930萬，導致淨虧損收窄至830萬，同比相比於1050萬。研究與開發費用增加19%，達到440萬，而銷售、一般及行政費用減少38%，降至490萬。公司強調最近的成就，包括正面結果的AVERt PRETERm試驗報告以及來自紐約州的環境全血採集的有條件批准。最終的PRIME研究數據庫預計將在九月中旬鎖定，出版目標爲春季懷孕會議。管理層正在執行各種成本有效的項目，以教育醫生和患者關於他們的PreTRM®測試，包括與醫療專業平台的合作和多渠道營銷策略。公司繼續專注於建立證據組合和制定護理指南，以推動採用和營業收入增長。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    艾里德克斯
    IRIX
    -- 0.999
    Helius Medical Technologies
    HSDT
    -- 0.4200
    VolitionRX
    VNRX
    -- 0.550
    HeartSciences
    HSCS
    -- 2.9600
    Outset Medical
    OM
    -- 12.580
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日